Novel therapeutic strategies for recurrent SCLC

Laura Moliner; Bingnan Zhang; Giuseppe Lamberti; Andrea Ardizzoni; Lauren A Byers; Raffaele Califano

doi:10.1016/j.critrevonc.2023.104017

Novel therapeutic strategies for recurrent SCLC

Crit Rev Oncol Hematol. 2023 Jun:186:104017. doi: 10.1016/j.critrevonc.2023.104017. Epub 2023 May 5.

Authors

Laura Moliner¹, Bingnan Zhang², Giuseppe Lamberti³, Andrea Ardizzoni⁴, Lauren A Byers⁵, Raffaele Califano⁶

Affiliations

¹ Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.
² Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
³ Department of Specialized, Experimental and Diagnostic Medicine, University of Bologna, Bologna 40138, Italy.
⁴ Department of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna 40138, Italy.
⁵ Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
⁶ Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK; Division of Cancer Sciences, The University of Manchester, Manchester M13 9NT, UK. Electronic address: raffaele.califano@nhs.net.

PMID: 37150311
DOI: 10.1016/j.critrevonc.2023.104017

Abstract

Therapeutic options for patients with relapsed SCLC are limited, and the prognosis in this setting remains poor. While clinical outcomes for frontline treatment have modestly improved with the introduction of immunotherapy, treatment in the second-line setting persists almost unchanged. In this review, current treatment options and recent advances in molecular biology are described. Emerging therapeutic options in this setting, and potential strategies to improve clinical outcomes of these patients are also addressed.

Keywords: Biomarker, precision medicine; Recurrent; Relapsed; SCLC; Second-line; Subtype; Targeted treatment.

Publication types

Review

MeSH terms

Humans
Immunotherapy
Lung Neoplasms* / drug therapy
Lung Neoplasms* / therapy
Neoplasm Recurrence, Local / drug therapy
Prognosis
Small Cell Lung Carcinoma* / drug therapy